Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Oncoc4 Inc.
Headquarters: Rockville, MD, United States of America
Website: https://oncoc4.com/
Year Founded: 2020
Status: Private
BioCentury | Oct 1, 2024
Deals
Prime narrows gene editing focus with BMS deal
Deals Report: Novartis-Generate use AI to develop protein therapies, and updates from Roche-Regor, CSPC-Alphamab and more
BioCentury | Apr 19, 2024
Management Tracks
Doug Williams leaving Sana
Plus: Baptista joins SmartCella and updates from LifeArc and Gain
BioCentury | Sep 28, 2023
Management Tracks
Expanded role for Gaito at J.P. Morgan
Plus: Peptone hires a new CSO, names Gritstone’s Allen chair, and updates from Foresite, OncoC4, Sibylla, Cell-Easy and Photocure
BioCentury | Jun 2, 2023
Product Development
June 2 Quick Takes: Kisqali cuts recurrence risk in broad breast cancer population
Plus: BioNTech, OncoC4 build case for CTLA-4 product with lung cancer readout, and updates from Takeda, Poseida, Canbridge and more
BioCentury | Apr 3, 2023
Deals
BioNTech breaks into ADCs, gains HER2-targeting product in deal with DualityBio
Cash-rich German biotech enters agreement with ambitious China-based company around potential competitors to Enhertu, Daiichi products
BioCentury | Mar 20, 2023
Deals
BioNTech sees differentiation in OncoC4’s CTLA-4, commits $200M up front
German biotech to explore combinations with molecule engineered to affect tumor microenvironment without triggering unwanted autoimmune effects
BioCentury | Nov 4, 2021
Management Tracks
Hoelscher to retire from Horizon
Plus: Ipsen, MaxCyte, Cara, Fusion and more
BioCentury | Oct 13, 2021
Management Tracks
Harler joins IGM as president of autoimmunity and inflammation business
Plus: Precigen, Transition Bio, Shoreline, Syros, Twist, Vor and more
Items per page:
1 - 8 of 8